Dr Goli Samimi
Goli has been involved in ovarian cancer research since 1999. She obtained her PhD degree in Biomedical Sciences from the University of California, San Diego (USA), where her research focused on the characterisation of the copper transporter ATP7A in platinum-based chemotherapy resistance. She was then accepted into the Cancer Prevention Fellowship Program at the National Cancer Institute, National Institutes of Health (USA), and obtained a Master of Public Health (MPH) degree.
Goli’s post-doctoral research focused on gene expression profiling to identify novel therapeutic targets for ovarian cancer treatment, and her findings revealed tumour-stromal interactions that are vital for ovarian cancer progression and metastasis. Goli then joined the Garvan’s Cancer Research Division in Feb 2011 as Head of the Ovarian Cancer Research Group, with research focused on the development of an early detection test for ovarian cancer, as well as further characterisation of tumour-stromal interactions to identify novel therapeutic targets.
Goli currently serves on the Editorial Boards of PLOS One and Scientific Reports, as well as serving on various committees including the ANZ Gynaecological Oncology Group (ANZGOG) Ovarian Tumours Working Group, and the Workplace Equity Committee (Garvan Institute). She has also organised and participated in numerous career development workshops including the AACR Translational Workshop for PhD Scientists, American Association for Cancer Research (USA) and the National Science Foundation ADVANCE Program, Faculty Horizons Workshop (USA).
Society memberships include the American Association for Cancer Research (AACR), the Tumor Microenvironment Working Group (AACR), the Molecular Epidemiology Working Group (AACR), American Association for Cancer Research, Women in Research Network (UNSW), Sydney Catalyst, ANZ Gynaecological Oncology Group (ANZGOG). Goli has had her research covered by various media outlets including Sky News, ABC Radio, Channel 7 (Australia), Channel 9 (Australia), Channel 10 (Australia), The Project (Australia), 938LIVE Body & Soul (Singapore), several featured articles from Fairfax, News Limited and AAP; Prevention, Daily Telegraph, Herald Sun, The Age, Australia Women’s Health, Sydney Morning Herald, Sky News, Daily Telegraph, Women in Teal, Women Scientist in Action.
In the NewsGarvan scientist selected to set ovarian cancer prevention research priorities in US - May 07, 2015
Aussie generosity still vital following medical future fund announcement - Jun 06, 2014
Tour de Cure’s pedal power raises $100,000 for Ovarian Cancer research - Mar 14, 2014
Overwhelming response for Ovarian Cancer Awareness Day Leader’s Lunch - Feb 28, 2014
Awards and Honours
2009-2014 - NIH K99/R00 Pathway To Independence Award (CA140713-01), Characterization of Stromal-Epithelial Interactions in Ovarian Cancer, National Cancer Institute, National Institutes of Health, USA
2005-2009 - Cancer Prevention Post-Doctoral Fellowship, National Cancer Institute, National Cancer Institute, National Institutes of Health, USA
2004 - PhD, University of California, San Diego, La Jolla, CA - USA
1997 - BS, University of California, Los Angeles, Los Angeles, CA - USA
Warton K, Lin V, Navin T, Armstrong NJ, Kaplan W, Ying K, Gloss B, Mang H, Nair SS, Hacker NF, Sutherland RL, Clark SJ and Samimi G. Methylation-capture and Next-Generation Sequencing of free circulating DNA from human plasma. BMC Genomics 15(1):476, 2014.
Gloss B, Moran-Jones K, Lin V, Gonzalez M, Scurry J, Hacker NF, Sutherland RL, Clark SJ* and Samimi G*. ZNF300P1 Encodes a lincRNA that regulates cell polarity and is epigenetically silenced in type II epithelial ovarian cancer. Mol Cancer 13(1):3, 2014.
Scott CL, Becker MA, Haluska P and Samimi G. Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front Oncol 3:295, 2013.
Gloss BS and Samimi G. Epigenetic biomarkers in epithelial ovarian cancer. Cancer Lett 342(2):257–263, 2014.
Yeung TL , Leung C, Dr. Wong K-K, Samimi G, Thompson MS, Liu J, Zaid T, Ghosh S, Birrer MJ and Mok SC. TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res 73(16):5016-5028, 2013.
Samimi G, Ring BZ, Ross DT, Sietz RS, Sutherland RL, O’Brien PM, Hacker NF and Huh WK. TLE3 expression is associated with sensitivity to paclitaxel treatment in ovarian carcinoma. Cancer Epidemiol Biomarkers Prev 21(2):273-279, 2012.
Montavon C, Gloss BS, Warton K, Barton CA, Statham AL, Scurry JP, Tabor B, Nguyen TV, Qu W, Samimi G, Hacker NF, Sutherland RL, Clark SJ, O’Brien PM. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol 124(3):582-588, 2012.
Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, Barrett JC, Wong WH, Welch WR, Berkowitz RS, Birrer MJ. A gene signature predictive for outcome in advanced ovarian cancer identifies a novel survival factor: microfibril-associated glycoprotein 2. Cancer Cell 16(6):521-532, 2009.
Samimi G, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, Safaei R and Howell SB. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin and oxaliplatin in ovarian cancer cells. Clin Cancer Res 10(14):4661-4669, 2004. Cover Article.
Samimi G, Varki NM, Wilczynski S, Safaei R, Alberts DS and Howell SB. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res 9(16 pt 1):5853-5859, 2003. Cover Article.
Accompanying Editorial: Kruh GD. Lustrous insights into cisplatin accumulation: copper transporters. Clin Cancer Res 9(16 pt 1):5807-5809, 2003.
Samimi G, Fink D, Varki NM, Husain A, Hoskins WJ, Alberts DS and Howell SB. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res 6(4):1415-1421, 2000.